CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA

NCT05299476 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastroesophageal Adenocarcinoma
First-line Therapy
PDL1 CPS < 5

Interventions

DRUG: CAPOX combined with bevacizumab and Tislelizumab

Sponsor

Chinese PLA General Hospital